Veru Inc. (NASDAQ) shares gained more than 30% in pre-market trading following the acquisition of Veru Inc. announcedIn Phase 3, the COVID-19 drug candidate was able to reduce deaths in COVID hospital patients by 55%. Independent Data Safety Monitoring Committee unanimously recommended stopping the Phase 3 trial due to “overwhelming success”. It also pointed out that no safety problems were found.